Effect of Spironolactone on Urinary Protein Excretion in Patients with Chronic Kidney Disease

Figures & data

Figure 1. The course of total proteinuria throughout treatment.

Table 1  The laboratory results, blood pressure values obtained prior to treatment and at four and eight weeks of treatment, and the relationship between them

Variable	Pre-treatment	4th week	8th week	p
Proteinuria (mg/d)	2774.90 ± 3216.55,median:1428.00	2093.84 ± 2595.76,median:1064.00	1834.42 ± 2293.14,median: 743.00	<0.001^†
Systolic blood pressure (mmHg)	132.42 ± 19.53	126.66 ± 15.54	125.30 ± 16.67	0.004^†
Diastolic blood pressure (mmHg)	83.18 ± 10.59	79.39 ± 9.33	76.66 ± 10.50	<0.001^†
Serum potassium level (mEq/L)	4.50 ± 0.35	4.78 ± 0.43	5.05 ± 0.67	<0.001^†
Blood urea nitrogen (mg/dl)	17.96 ± 9.43	19.33 ± 11.72	19.84 ± 10.37	0.030
Creatinine clearance (ml/min/1.73 m^2)	103.03 ± 42.34	106.54 ± 44.36	100.58 ± 41.10	>0.05
Serum creatinine level (mg/dl)	1.09 ± 0.44	1.10 ± 0.48	1.10 ± 0.38	>0.05

*p < 0.05, ^†p < 0.01.

Table 2  The baseline characteristics of the patients with and without hyperkalemia

Variable	Potassium < 5.5	Potassium ≥ 5.5	p
Age (years)	43.22 ± 15.11	54.16 ± 4.07	0.003
Serum potassium level (mEq/L)	4.45 ± 0.36	4.70 ± 0.13	0.006
Creatinine clearence (ml/min/1.73m^2)	107.34 ± 43.44	83.65 ± 33.25	0.220
Serum creatinine level (mg/dl)	1.02 ± 0.31	1.43 ± 0.77	0.145

*p < 0.05.